

Proposed evidence review group (ERG) on the community effect of insecticide treated nets



Malaria Policy Advisory Committee Meeting

Geneva, Switzerland

17 – 19 October 2018

Global **Malaria** Programme




**World Health
Organization**



- Support a move from expert opinion to evidence-based recommendations
- Articulate certainty of evidence in GRADE tables
- Provide evidence-to-decision frameworks for each intervention
- Incorporate existing recommendations in attempt to condense large volume of guidance into one resources








Page 2. ITNs: Mode of action: By reducing the vector population in this way, ITNs, when used by a majority of the target population, provide protection for all people in the community, including those who do not themselves sleep under nets (1, 2). A recent study has shown that relatively modest coverage (**around 60%**) of all adults and children can achieve equitable **community-wide benefits** (3).

Page 8. Full coverage: Since high coverage rates are needed to realize the full potential of LLINs, GMP recommends **full coverage** of all people at risk in areas targeted for malaria prevention through ITNs, including LLINs.



1. Binka *et al.* (1998) Impact of spatial distribution of permethrin-impregnated bed nets on child mortality in rural northern Ghana. *Am J Trop Med Hyg* 59: 80-5
2. Hawley *et al.* (2003) Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya. *Am J Trop Med Hyg* 68: 121-27.
3. Killeen *et al.* (2007) Preventing childhood malaria in Africa by protecting adults from mosquitoes with insecticide-treated nets. *PLoS Med* 4(7): e229.




- Evidence underpinning universal coverage recommendation needs to be comprehensively reviewed and be clearly laid out
- Recommendation needs to be articulated by means of an evidence-to-decision framework





Dr Tedros Adhanom Ghebreyesus
Director-General
World Health Organization



For many years, the global response to malaria was considered one of the world's great public health achievements. WHO reported time and again on the massive roll-out of effective disease-cutting tools, and on impressive reductions in cases and deaths.

Last December, we noted a troubling shift in the trajectory of this disease. The data showed that less than half of countries with ongoing transmission were on track to reach critical targets for reductions in the death and disease caused by malaria. **Progress appeared to have stalled.**

The World malaria report 2017 shows that this worrying trend continues. Although there are some bright spots in the data, the overall decline in the global malaria burden has unquestionably leveled off. And, in some countries and regions, we are beginning to see reversals in the gains achieved.



The 10+1 Initiative an intensified effort to reduce malaria cases and deaths

Getting back on track to achieve the
WHO Glob



Global **Malaria** Pro

What is new...

- Highest political and financial dialogue
 - Raise profile of malaria, particularly at country level
 - Domestic financing
- Focused on reducing deaths
 - With current available tools, no-one should die
- Moving from blanket to granular data for action – to **prioritize interventions** (stratification)

Global **Malaria** Programme



Prioritization






Cutting the cake differently does not change its size




In other words, prioritizing one intervention over another requires de-prioritization of one or more alternatives.

The decision to do so should be evidence-based.





- One of two WHO recommended core vector control interventions



- Target since 2007 is universal coverage, which has significant resource implications

Note: Universal coverage is defined as universal access to and use of appropriate interventions by populations at risk of malaria.







Figure 3. Value of Global F und NFM support to vector control approaches



Over 2000 – 2015, an estimated 663 million clinical cases averted, 68% of which by ITNs, at coverage levels well below universal coverage

Bhatt *et al.* (2015) The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature* 526(7572): 207–11.




Koenker *et al.* (2018) Assessing whether universal coverage with insecticide-treated nets has been achieved: is the right indicator being used? *Malaria J* 17: 355.

Efficiency: observations




- Low coverage (43% in 2013)
- Uneven net distribution among households (21% over-allocated)
- Over-allocation worsened as net provision increased
- Rapid rates of net loss from households (50% lost after 23 months)



Bhatt *et al.* (2015) Coverage and system inefficiencies of insecticide-treated nets in Africa from 2000 to 2017. eLife 4:e09672.

Efficiency: conclusions



- Quantity estimated to achieve universal coverage would in reality yield much lower level coverage
- Identified system inefficiencies are not easily overcome
- Diminishing coverage returns for each dollar spent
- Cost-effectiveness of pursuing universal coverage rather than a lower operational target must be weighed against alternative malaria control investments

Bhatt *et al.* (2015) Coverage and system inefficiencies of insecticide-treated nets in Africa from 2000 to 2017. *eLife* 4:e09672.

(Some) key questions



- What is the current evidence-base underpinning WHO's universal coverage recommendation? What are the evidence gaps?
- Is the recommendation primarily driven by easier communication and operational considerations, or is there an actual threshold that is needed for ITNs to achieve maximum impact (and/or a community (mass) effect)?
- What is the relative contribution of personal protection and a community effect? How may pyrethroid resistance affect these?
- Is the community effect generalizable or only applicable in certain settings?
- Should countries unable to achieve universal coverage be concerned about this and continue to pursue this goal?
- What evidence-based recommendation should be provided to countries unable to finance universal ITN coverage of all at-risk populations?





- To **appraise a systematic review** of the available evidence on the community effect of ITNs, which will include an analysis of the presence/absence/variations of this effect depending on geographical setting, coverage level and the prevalence/intensity of pyrethroid resistance
- To **advise WHO** on whether the findings from the review of the evidence-base on the community effect of ITNs warrant a **revision of current WHO guidance on the deployment of ITNs**
- To **review the WHO glossary** to verify whether definitions regarding ITNs and their personal and community effect are appropriately captured. If required, the ERG will need to **recommend additions or edits** to the glossary to ensure that the definitions are valid and appropriate



- Is the convening of the proposed ERG meeting supported in principle?
- Do the proposed objectives accurately reflect current needs or are modifications to the ERG ToRs required?